Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
LANTERN PHARMA INC (LTRN) Stock Price & Overview
NASDAQ:LTRN • US51654W1018
Current stock price
2.12 USD
+0.07 (+3.41%)
At close:
2.1904 USD
+0.07 (+3.32%)
After Hours:
The current stock price of LTRN is 2.12 USD. Today LTRN is up by 3.41%. In the past month the price increased by 30.86%. In the past year, price decreased by -40.11%.
LTRN Key Statistics
52-Week Range1.11 - 5.7441
Current LTRN stock price positioned within its 52-week range.
1-Month Range1.5 - 2.82
Current LTRN stock price positioned within its 1-month range.
- Market Cap
- 23.85M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.57
- Dividend Yield
- N/A
LTRN Stock Performance
Today
+3.41%
1 Week
-13.82%
1 Month
+30.86%
3 Months
-32.70%
Longer-term
6 Months -47.13%
1 Year -40.11%
2 Years -65.07%
3 Years -59.31%
5 Years -85.98%
10 Years N/A
LTRN Stock Chart
LTRN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LTRN. When comparing the yearly performance of all stocks, LTRN is a bad performer in the overall market: 92.31% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
LTRN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LTRN. The financial health of LTRN is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LTRN Earnings
Next Earnings DateMay 5, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.36
Revenue Reported
EPS Surprise 23.27%
Revenue Surprise %
LTRN Forecast & Estimates
7 analysts have analysed LTRN and the average price target is 25.5 USD. This implies a price increase of 1102.83% is expected in the next year compared to the current price of 2.12.
Analysts
Analysts82.86
Price Target25.5 (1102.83%)
EPS Next Y-24.09%
Revenue Next YearN/A
LTRN Index Membership
LTRN is currently included in the following stock indexes tracked on ChartMill.
LTRN Financial Highlights
Over the last trailing twelve months LTRN reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS increased by 18.65% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-17.12M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -155.13% | ||
| ROE | -262% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%33.33%
Sales Q2Q%N/A
EPS 1Y (TTM)18.65%
Revenue 1Y (TTM)N/A
LTRN Ownership
Ownership
Inst Owners19.84%
Shares11.25M
Float9.16M
Ins Owners0.41%
Short Float %19.01%
Short Ratio2.49
LTRN Industry Overview
LTRN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
LTRN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LTRN
Company Profile
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Company Info
IPO: 2020-06-11
LANTERN PHARMA INC
1920 Mckinney Avenue, 7th Floor
Dallas TEXAS 75201 US
CEO: Panna Sharma
Employees: 24
Phone: 19722771136
LANTERN PHARMA INC / LTRN FAQ
Can you describe the business of LANTERN PHARMA INC?
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 24 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
What is the current price of LTRN stock?
The current stock price of LTRN is 2.12 USD. The price increased by 3.41% in the last trading session.
What is the dividend status of LANTERN PHARMA INC?
LTRN does not pay a dividend.
How is the ChartMill rating for LANTERN PHARMA INC?
LTRN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is LANTERN PHARMA INC worth?
LANTERN PHARMA INC (LTRN) has a market capitalization of 23.85M USD. This makes LTRN a Nano Cap stock.
Can you provide the ownership details for LTRN stock?
You can find the ownership structure of LANTERN PHARMA INC (LTRN) on the Ownership tab.
What is the Short Interest ratio of LANTERN PHARMA INC (LTRN) stock?
The outstanding short interest for LANTERN PHARMA INC (LTRN) is 19.01% of its float.